Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • Invest in the Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • News Releases
  • Invest in the Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

April 6, 2022

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

March 30, 2022

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

March 17, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

RSS
  • « Previous
  • 1...
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...30
  • Next »

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Aug 25, 2025

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read More...
Aug 20, 2025

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Read More...
Aug 18, 2025

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Read More...
Copyrights © 2025 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap